X-ray structure of human acid-β-glucosidase covalently bound to conduritol-B-epoxide -: Implications for Gaucher disease.

被引:89
作者
Premkumar, L
Sawkar, AR
Boldin-Adamsky, S
Toker, L
Silman, I
Kelly, JW
Futerman, AH [1 ]
Sussman, JL
机构
[1] Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel
[2] Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel
[3] Weizmann Inst Sci, Dept Biol Struct, IL-76100 Rehovot, Israel
[4] Scripps Res Inst, Dept Chem, La Jolla, CA 92037 USA
[5] Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA
关键词
D O I
10.1074/jbc.M502799200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Gaucher disease is an inherited metabolic disorder caused by mutations in the lysosomal enzyme acid-beta-glucosidase (GlcCerase). We recently determined the x-ray structure of GlcCerase to 2.0 angstrom resolution (Dvir, H., Harel, M., McCarthy, A. A., Toker, L., Silman, I., Futerman, A. H., and Sussman, J. L. ( 2003) EMBO Rep. 4, 704-709) and have now solved the structure of GlcCerase conjugated with an irreversible inhibitor, conduritol-B- epoxide ( CBE). The crystal structure reveals that binding of CBE to the active site does not induce a global conformational change in GlcCerase and confirms that Glu(340) is the catalytic nucleophile. However, only one of two alternative conformations of a pair of flexible loops ( residues 345-349 and 394-399) located at the entrance to the active site in native GlcCerase is observed in the GlcCerase-CBE structure, a conformation in which the active site is accessible to CBE. Analysis of the dynamics of these two alternative conformations suggests that the two loops act as a lid at the entrance to the active site. This possibility is supported by a cluster of mutations in loop 394-399 that cause Gaucher disease by reducing catalytic activity. Moreover, in silico mutational analysis demonstrates that all these mutations stabilize the conformation that limits access to the active site, thus providing a mechanistic explanation of how mutations in this loop result in Gaucher disease.
引用
收藏
页码:23815 / 23819
页数:5
相关论文
共 29 条
[1]  
Amaral O, 1996, HUM MUTAT, V8, P280, DOI 10.1002/(SICI)1098-1004(1996)8:3<280::AID-HUMU15>3.3.CO
[2]  
2-6
[3]   Gaucher disease:: expression and characterization of mild and severe acid β-glucosidase mutations in Portuguese type 1 patients [J].
Amaral, O ;
Marcao, A ;
Miranda, MCS ;
Desnick, RJ ;
Grace, ME .
EUROPEAN JOURNAL OF HUMAN GENETICS, 2000, 8 (02) :95-102
[4]  
BEUTLER E, 1994, HUM GENET, V93, P209
[5]  
Beutler E., 2001, METABOLIC MOL BASES, V3, P3635
[6]  
Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/s0907444998003254
[7]  
CHU FK, 1986, J BIOL CHEM, V261, P172
[8]   HUMAN ACID BETA-GLUCOSIDASE - ISOLATION AND AMINO-ACID-SEQUENCE OF A PEPTIDE CONTAINING THE CATALYTIC SITE [J].
DINUR, T ;
OSIECKI, KM ;
LEGLER, G ;
GATT, S ;
DESNICK, RJ ;
GRABOWSKI, GA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1986, 83 (06) :1660-1664
[9]   A contradictory treatment for lysosomal storage disorders: inhibitors enhance mutant enzyme activity [J].
Fan, JQ .
TRENDS IN PHARMACOLOGICAL SCIENCES, 2003, 24 (07) :355-360
[10]   New directions in the treatment of Gaucher disease [J].
Futerman, AH ;
Sussman, JL ;
Horowitz, M ;
Silman, I ;
Zimran, A .
TRENDS IN PHARMACOLOGICAL SCIENCES, 2004, 25 (03) :147-151